StockNews.AI
SLQT
StockNews.AI
71 days

SelectQuote (SLQT) Shares Slide Further on Disappointing Earnings Amidst DOJ Scrutiny – Hagens Berman

1. SLQT shares dropped 12% post-earnings miss and DOJ lawsuit. 2. Earnings of $0.03 per share missed estimates of $0.04. 3. Revenues of $408 million fell short of $417 million estimate. 4. DOJ lawsuit accuses SLQT of violating the False Claims Act. 5. Investors encouraged to join legal investigations due to losses.

Earnings
-1.14%Current Return
VS
+0.49%S&P 500
$2.206/09 09:14 AM EDTEvent Start
$2.17506/10 03:44 PM EDTLatest Updated
6m saved
Insight
Article

FAQ

Why Very Bearish?

The combination of earnings misses and legal troubles drastically undermines investor confidence, reminiscent of past instances where companies faced dual pressures of financial underperformance and litigation, significantly impacting stock prices. For instance, similar situations in 2019 with various pharmaceutical firms resulted in stock drops of over 30%.

How important is it?

The ongoing DOJ lawsuit and missed earnings report are critical factors that are likely to continue affecting SLQT's price due to heightened investor dissatisfaction and legal scrutiny. Investors' reactions to these factors suggest an ongoing scenario of uncertainty regarding the company's future.

Why Short Term?

Investor sentiment is currently highly responsive to immediate news and earnings reports, as seen with the immediate drop in share price following the issues presented in the article. Significant legal investigations tend to instigate immediate stock volatility coupled with negative sentiment.

Related Companies

AETANTMHUM
SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- SelectQuote Inc. (NYSE: SLQT) faced renewed investor pressure on Monday, May 12, 2025, as its shares tumbled another 12% following the release of quarterly results that fell short of earnings and revenue expectations. This decline compounds the over 19% drop experienced on May 1st after the U.S. Department of Justice (DOJ) announced a lawsuit alleging violations of the False Claims Act against the insurance brokerage and several major health insurers. Hagens Berman is investigating potential violations of the U.S. securities laws and encourages SelectQuote investors who suffered substantial losses to submit your losses now. The firm also urges persons with knowledge who may be able to assist in the investigation to contact its attorneys. Visit: www.hbsslaw.com/investor-fraud/slqt Contact the Firm Now: SLQT@hbsslaw.com                                              844-916-0895 Earnings Miss Adds to Investor Woes For the quarter ended March 2025, SelectQuote reported earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share. The company also posted revenues of $408.16 million, falling short of the Zacks Consensus Estimate of $417.01 million by 2.12%. Mounting Troubles Weigh on Investor Confidence This financial disappointment adds to the headwinds facing SelectQuote, which is already grappling with serious legal allegations. The DOJ lawsuit, unveiled on May 1st, accuses SelectQuote, along with other brokers and health insurance giants Aetna, Anthem, and Humana, of False Claims Act violations related to the marketing of Medicare Advantage (MA) plans. The lawsuit alleges that, from 2016 through at least 2021, insurers paid significant sums to SelectQuote and other brokers for Medicare Advantage enrollments. The DOJ contends that, rather than providing unbiased guidance, SelectQuote and other brokers steered beneficiaries toward plans offering the highest commissions, potentially disregarding the suitability of those plans. The complaint further details allegations of incentivizing sales based on these commissions, establishing dedicated sales teams for specific high-commission plans, and instances of allegedly refusing to sell plans from insurers with lower commission structures. Discrimination against MA beneficiaries with disabilities is also alleged. Hagens Berman’s Investigation The confluence of a weaker-than-anticipated earnings report and ongoing legal entanglements has amplified anxieties surrounding SelectQuote's financial stability and operational integrity. According to Reed Kathrein, the Hagens Berman partner spearheading an inquiry into the company, “The recent earnings figures underscore our existing concerns about SelectQuote's alleged steering tactics in light of the DOJ's allegations.” If you invested in SelectQuote and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now » If you’d like more information and answers to frequently asked questions about the SelectQuote investigation, read more » Whistleblowers: Persons with non-public information regarding SelectQuote should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SLQT@hbsslaw.com. About Hagens BermanHagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.  Contact: Reed Kathrein, 844-916-0895

Related News